Mitochondria-targeted carbon monoxide delivery combined with iron chelation therapy for cancer synergistic treatment
Colloids and Surfaces B: Biointerfaces · 2026-08 · 264 · 115658
DOI: 10.1016/j.colsurfb.2026.115658 ↗Kurz gefasst
Fachartikel in der Zeitschrift Colloids and Surfaces B: Biointerfaces, 2026-08. Verfasst von Cheng-Bin Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Advanced Materials, School of Chemistry & Molecular Engineering, East China University of Science and Technology, Shanghai 200237,…. Hauptthemen laut MEDLINE: Carbon Monoxide, Mitochondria, Iron Chelating Agents, Deferasirox. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Fundamental Research Funds for Central Universities of the Central South University, Fundamental Research Funds for the Central Universities, Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning.
Abstract (Originalsprache)
Carbon monoxide (CO) effectively induces mitochondrial metabolic collapse by disrupting oxidative phosphorylation for cancer therapy, while its clinical translation is hindered by inefficient mitochondrial delivery and redox homeostasis maintained via mitochondrial iron regulation. To overcome these limitations, we engineered a mitochondria-targeted CO delivery strategy synergized with deferasirox (DFX)-mediated iron chelation. A mitochondria-directed CO donor, TPPMnCO, was synthesized by coordinating manganese carbonyl complexes with a triphenylphosphine-derived ligand (TPPPy). Subsequently, TPPMnCO and DFX were covalently attached to nitrogen-doped graphene quantum dots (N-GQDs), yielding a multifunctional nanoplatform DFX@TPPMnCO@N-GQDs. Under 808 nm NIR irradiation, this nanoplatform selectively accumulates in tumor mitochondria, triggering CO release to induce apoptosis while DFX disrupts iron homeostasis, synergistically amplifying mitochondrial metabolic failure. In vitro and in vivo studies confirmed the nanoplatform's biosafety and excellent tumor suppression efficacy, establishing a paradigm-shifting strategy for gas therapy via iron homeostasis modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Advanced Materials, School of Chemistry & Molecular Engineering, East China University of Science and Technology, Shanghai 200237, PR China.
- Key Lab of Resource Chemistry of MOE & Shanghai Key Lab of Rare Earth Functional Materials, Shanghai Normal University, Shanghai 200234, PR China.
- Key Laboratory for Advanced Materials, School of Chemistry & Molecular Engineering, East China University of Science and Technology, Shanghai 200237, PR China. Electronic address: liujingang@ecust.edu.cn.
Förderung
- Fundamental Research Funds for Central Universities of the Central South University
- Fundamental Research Funds for the Central Universities
- Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning
- National Natural Science Foundation of China
Zitieren
APA
Wang, C. B., Tang, Q., Mao, J. Z., Yang, S. P., & Liu, J. G. (2026). Mitochondria-targeted carbon monoxide delivery combined with iron chelation therapy for cancer synergistic treatment. Colloids and Surfaces B: Biointerfaces, 264, 115658. https://doi.org/10.1016/j.colsurfb.2026.115658
Vancouver
Wang CB, Tang Q, Mao JZ, Yang SP, Liu JG. Mitochondria-targeted carbon monoxide delivery combined with iron chelation therapy for cancer synergistic treatment. Colloids and Surfaces B: Biointerfaces. 2026;264:115658. doi:10.1016/j.colsurfb.2026.115658
BibTeX
@article{Wang2026,
author = {Wang, Cheng-Bin and Tang, Qi and Mao, Jian-Zhi and Yang, Shi-Ping and Liu, Jin-Gang},
title = {Mitochondria-targeted carbon monoxide delivery combined with iron chelation therapy for cancer synergistic treatment},
journal = {Colloids and Surfaces B: Biointerfaces},
year = {2026},
volume = {264},
pages = {115658},
doi = {10.1016/j.colsurfb.2026.115658}
}
EUVIMED